21-184 Phase I
A Phase 1, First-in-Human Study of DCC-3116 as a Single Agent and in Combination with Trametinib in Patients with Advanced or Metastatic Solid Tumors with RAS or RAF Mutations
Search Cancer Clinical Trials
Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
49 results
23-452 Phase I
A Phase 1, First-in-Human, Dose Escalation and Expansion Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
25-022 Phase I
A Phase 1, Open-Label Dose Escalation and Expansion Study of PT0253 in Participants with KRAS G12D Mutated Advanced Solid Tumors
17-330 Phase I
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors
22-430 Phase II
A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
23-340 Phase II
A Phase 1/2 Study of FOG-001 in Participants with Locally Advanced or Metastatic Solid Tumors
17-241 Phase I
A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)
23-679 Phase II
A Phase 1/2 Study of PRO1107 in Patients with Advanced Solid Tumors
21-466 Phase II
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)
22-323 Phase II
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
Showing 11 - 20 of 49 results